Head-To-Head Analysis: Eton Pharmaceuticals (NASDAQ:ETON) vs. Incannex Healthcare (NASDAQ:IXHL)

Incannex Healthcare (NASDAQ:IXHL) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Incannex Healthcare and Eton Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	2	0	1	0	1.67
Eton Pharmaceuticals	0	1	5	0	2.83

Incannex Healthcare currently has a consensus target price of $18.00, suggesting a potential upside of 791.09%. Eton Pharmaceuticals has a consensus target price of $79.75, suggesting a potential upside of 29.78%. Given Incannex Healthcare’s higher possible upside, research analysts plainly believe Incannex Healthcare is more favorable than Eton Pharmaceuticals.

Institutional and Insider Ownership

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 9.1% of Incannex Healthcare shares are held by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Incannex Healthcare and Eton Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-25.62%	-24.46%
Eton Pharmaceuticals	35.35%	104.82%	43.09%

Earnings and Valuation

This table compares Incannex Healthcare and Eton Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90,000.00	281.68	-$19.30 million	($1.69)	-1.20
Eton Pharmaceuticals	$79.95 million	22.17	-$4.60 million	$1.51	40.70

Eton Pharmaceuticals has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Incannex Healthcare has a beta of 7, suggesting that its stock price is 600% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Summary

Eton Pharmaceuticals beats Incannex Healthcare on 11 of the 14 factors compared between the two stocks.

About Incannex Healthcare

Incannex Healthcare Limited (NASDAQ: IXHL) is an Australia-based clinical-stage pharmaceutical company developing cannabinoid- and psychedelic-assisted therapies for conditions with significant unmet medical needs. The company’s research programs are focused on areas including sleep disorders, pain, inflammation, mental health and traumatic brain injury. Incannex’s lead programs have included IHL-42X, an investigational combination therapy being developed for obstructive sleep apnea, and IHL-675A, a cannabinoid-based therapy studied for inflammatory conditions.

About Eton Pharmaceuticals

Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.